Form 4: Solid Biosciences CMO Sells Shares for Tax Obligations

Solid Biosciences' Chief Medical Officer, Gabriel Brooks, sold 12,616 shares of common stock to cover tax withholding related to RSU vesting.

Summary

• Gabriel Brooks, Chief Medical Officer of Solid Biosciences Inc. (SLDB), reported a sale of common stock.
• The transaction involved the disposition of 12,616 shares of Solid Biosciences common stock.
• The sale occurred on February 4, 2026, at a weighted average price of $6.4419 per share.
• The shares were sold in multiple transactions with prices ranging from $6.28 to $6.60, inclusive.
• This sale was a 'sell-to-cover' election, made to cover withholding taxes following the vesting of previously granted restricted stock units.
• The transaction was executed pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024, and does not represent a discretionary trade.
• Following this transaction, Dr. Brooks beneficially owns 84,092 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and solely for tax withholding purposes following the vesting of restricted stock units, rather than a reflection of management's outlook on the company's performance.

Future Outlook

NA

Management Comments

• This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election.
• The sale does not represent a discretionary trade by Dr. Brooks.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions, while insider sales, are typically non-discretionary and executed to satisfy tax obligations upon the vesting of equity awards, and thus are generally not indicative of management's sentiment regarding the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary insider transaction for tax purposes, not signaling a change in company fundamentals or management confidence.

Key Dates

Keywords

Solid Biosciences, SLDB, Insider Trading, Form 4, Gabriel Brooks, Chief Medical Officer, Stock Sale, Restricted Stock Units, Tax Withholding, Sell-to-Cover, Biotechnology